Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.
Superinvestors holding KROS, Q2 2026
No superinvestor reported holding KROS in Q2 2026.